LTR Pharma (ASX:LTP) Accounts Receivable : A$0.00 Mil (As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. LTR Pharma's accounts receivables for the quarter that ended in Jun. 2023 was A$0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. LTR Pharma's Net-Net Working Capital per share for the quarter that ended in Jun. 2023 was A$0.05.

LTR Pharma Accounts Receivable Historical Data

The historical data trend for LTR Pharma's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Accounts Receivable Chart

LTR Pharma Annual Data

Trend

Jun21

Jun22

Jun23

Accounts Receivable

LTR Pharma Semi-Annual Data
	Jun21	Jun22	Jun23
Accounts Receivable	-	-	-

LTR Pharma Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

LTR Pharma Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

LTR Pharma's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), LTR Pharma's accounts receivable are only considered to be worth 75% of book value:

LTR Pharma's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(7.145	+	0.75 * 0	+	0.5 * 0	-	0.021
-	0	-	0)	/	139.42
=	0.05

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

LTR Pharma Accounts Receivable Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma (ASX:LTP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

9A/204 Alice Street, Brisbane, QLD, AUS, 4000

Website

https://www.ltrpharma.com

LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines